Key Players
Competitive Landscape
Merchant suppliers are competing through named strains, local claims and licences rather than price alone. Novonesis holds Health Canada claims for CLEPIUS L. plantarum in adults with irritable bowel syndrome [18], while Lallemand widened its P17630 licence to all European territories in December 2025 [21]. These moves give food and supplement brands a ready-made claim route, which is expected to tie buyers to specific suppliers for longer.
Suppliers are also investing in output and new uses, as Lallemand is adding encapsulation capacity in France [7] and BioGaia is moving into colon health with a UK-first launch [10]. Competition will therefore centre on suppliers that can combine capacity, clinical data and country approvals.
Company developments mapped to drivers, trends and opportunities (2026-2036)
Table 8: Company Developments Mapped to Drivers, Trends and Opportunities for the Probiotic Strains Market (qualitative), mixed years
| Development | Driver | Trend | Opportunity |
|---|---|---|---|
| Novonesis | In September 2026, the West Allis expansion lifted fermentation capacity by about 66% [6] | Steady cultured dairy orders | Capacity additions by large culture suppliers | Supply larger dairy and supplement contracts |
| Probi | In May 2026, Probi and Nomura Dairy reported the first clinical study of LP299V in Japanese adults [19] | Need for local clinical evidence | Strain launches in food formats | Wider use of strains in drinks across Asia |
| BioGaia | In September 2026, BioGaia Colus with L. reuteri BG-R59 was announced for a UK launch [10] | Adult digestive health demand | Clinically backed adult products | Colon health as a new strain application |
Source: Future Market Insights, Probiotic Strains Market Report, 2026-2036.
Who Leads the Probiotic Strains Market?
Novonesis, which absorbed Chr. Hansen in January 2024 [23], leads merchant strain supply, with its Human Health business reporting EUR 494.8 million in 2025 sales [3]. Lallemand and Probi follow as focused strain licensors, while dairy and nutrition groups shape demand through their own products.
Which Companies Lead Merchant Culture and Strain Platforms?
Chr. Hansen (Novonesis), Lallemand and Probi lead, as they sell named strains and licences to other manufacturers [21] [11].
Which Companies Lead Food and Nutrition Formulation?
Danone, Yakult and Nestlé lead this group, as they use strains in their own dairy and nutrition products and shape what buyers specify.
Which Companies Lead Specialist Platforms?
BioGaia leads as a specialist strain brand with 2025 net sales of SEK 1,538.2 million [4], while DuPont is a historical profile after its 2021 divestiture [24].
Representative Company Overview
Table 9: Representative Company Overview for the Probiotic Strains Market (qualitative), mixed years
| Company | Positioning | Verified Development |
|---|---|---|
| Novonesis (Chr. Hansen) | Largest merchant culture and probiotic supplier | Completed the West Allis expansion with about 66% more fermentation capacity in September 2026 [6] |
| Lallemand Inc. | Strain licensor and producer for women's health and supplements | Secured European rights for oral L. plantarum P17630 in December 2025 [21] |
| Probi AB | Merchant strain platform active in over 40 markets | Added Sports & Active Nutrition and Pets areas in November 2025 [22] |
| BioGaia AB | Specialist L. reuteri probiotic brand | Announced the BioGaia Colus colon-health probiotic, starting in the UK, in September 2026 [10] |
Company Selection and Benchmark Notes
Companies were selected from the source report and grouped by their role in strain supply. Ratings are qualitative and based on public strain evidence, product or licence activity and sales routes. Chr. Hansen is assessed through Novonesis after the January 2024 combination, and DuPont is left unscored because its former probiotic portfolio moved to IFF in 2021. No company market shares are given.
